Regenetech to Present Adult Stem Cell Update at 2007 Texas Life Science Conference
David Bonner, CEO, stated, “Regenetech believes its technology enables tissue regeneration, and we look forward to updating the community on our recent developments at the Texas Life Science Conference.”
Regenetech is a Houston Technology Center Client Company that has built upon NASA-invented technology to allow adult stem cells separated from peripheral blood or umbilical cord blood samples to be expanded to therapeutic dose levels in six to seven days. This is done with the Intrifuge™ Bioreactor equipped with the NASA-patented Time-Varying Electromagnetic Field (TVEMF) system. In addition, Regenetech is in preclinical veterinary orthopedic trials using the TVEMF system as a medical device for rapid healing of damaged tissue and bone.
The Company has a dual track revenue strategy to maintain a balance between short and medium term earnings. On one hand, it licenses out technologies for treatments, which has the potential to secure near-term earnings. On the other hand, it is progressing adult stem cell therapies through the usual biologics clinical trials cycle, which is significantly shorter and less costly than the conventional drug clinical trials process.
The Texas Life Science Conference (TLSC) is a premier, annual life science venture capital conference bringing together the life science industry's preeminent venture capitalists, leading researchers, and emerging companies' executives from across the nation, representing some of the most revolutionary developments in the life sciences. Regenetech will be presenting its latest advances along with company presentations from the latest Texas Emerging Technology Fund (TETF) finalists.
Houston Technology Center (HTC) is a business accelerator that assists Houston-based emerging technology companies in key sectors such as: Energy, Information Technology, Life Sciences, Nanotechnology and NASA-originated technologies. See www.houstontech.org for more information.
For more information about Regenetech and investment and licensing opportunities, visit www.regenetech.com or contact email@example.com.